Adagene Inc.: Form 20-F for the period ended Dec 31, 2021
Filed with the SEC on Apr 26, 2022 and accepted by EDGAR at Apr 26, 2022, 20:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $10.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $68.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$72.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $363.8k | us-gaap:InterestExpense |
| Income tax | 12 months2021-01-01 to 2021-12-31 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$73.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | −$1.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | −$1.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 50,032,009 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$43.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $2.5m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 12 months2021-01-01 to 2021-12-31 | $2.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-12-31 | $174.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $186.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $189.5m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $29.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $33.0m | us-gaap:Liabilities |
| Long-term debt | At period end2021-12-31 | $3.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-12-31 | $1.4m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2021-12-31 | $156.6m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2021-12-31 | 54,595,667 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001104659-22-050329. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.